预防性或先发性疗法,以防止异性造血干细胞移植后复发
1Division of Hematology, Department of Internal Medicine, Jichi Medical University Saitama Medical Center, 1-847 Amanuma, Omiya-Ku, Saitama-City, Saitama, 330-8503, Japan. shinichikako@asahi-net.email.ne.jp.
供体淋巴细胞输液 (DLI) 和维持疗法可以防止全源干细胞移植后复发. 研究正在积累关于其有效性和安全性的证据,以改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 同源性造血干细胞移植为血液性恶性瘤提供治疗方法,但在复发方面面临挑战.
- 供体淋巴细胞输液 (DLI) 和移植后的维持疗法是减轻复发风险的关键策略.
- 本综述侧重于预防性/预防性DLI和分子向维护药物.
更多相关视频
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
相关概念视频
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Regulation of Hematopoietic Stem Cells
Cell-mediated Immune Responses
Tumor Immunotherapy
Multipotency of Hematopoietic Stem Cells
